MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Hologic, Inc. (Nasdaq: HOLX) announced today a multi-year strategic collaboration with Google Cloud that will feature the integration of Google Cloud?s machine learning (ML) technologies with Hologic?s cutting-edge?Genius? Digital Diagnostics System?to transform screening and accelerate the eradication of cervical cancer across the globe.

This press release features multimedia. View the full release here:?https://www.businesswire.com/news/home/20210201005885/en/

Genius Digital Diagnostics is the first digital cytology platform to combine artificial intelligence (AI) with advanced digital imaging to help identify pre-cancerous lesions and cancer cells in women. Now, Hologic is enhancing the deep learning component of the system with Google Cloud. The expectation is that the Genius Digital Diagnostics System will derive even more actionable insights from cytology slides for cytotechnologists and pathologists. Google Cloud also provides a secure and reliable cloud data architecture to further extend the system?s capabilities. ?Hologic has been at the forefront of cervical cancer screening for more than 30 years, and we are building on that legacy with this strategic collaboration,? said Kevin Thornal, President of Hologic?s Diagnostic Solutions Division. ?Enhancing our use of AI with Google Cloud?s machine learning capabilities and cloud architecture is the next natural step in this journey forward.? Hologic is conducting research to explore the meaningful differences working at the intersection of AI and ML can have within diagnostics, improving laboratory performance, healthcare provider decision-making, and ultimately patient care. ?Through this collaboration with Hologic, we are helping to evolve digital diagnostics by complementing their expertise in diagnostics and AI with our expertise in machine learning,? said Joe Miles, Managing Director of Google Cloud Healthcare and Life Sciences. ?We are further bringing to life our two organizations? shared commitment to reimagining digital diagnostic capabilities for laboratories and healthcare providers across the globe, ultimately enabling them to better serve their patients.? Genius Digital Diagnostics is CE-marked for diagnostic use in Europe and is not available for sale in the United States. Financial terms of the collaboration were not disclosed. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women?s health and well-being through early detection and treatment. For more information on Hologic, visit?www.hologic.com. Hologic Forward-Looking Statements This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic?s diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based. Hologic, Genius and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries. Source: Hologic, Inc.

View source version on?businesswire.com:?https://www.businesswire.com/news/home/20210201005885/en/

Media Contact: Jane Mazur 508.263.8764 (direct) 585.355.5978 (mobile) jane.mazur@hologic.com Investor Contact: Michael Watts 858.410.8588 michael.watts@hologic.com Source: Hologic, Inc.